MedPath

Evaluation of the effect of Angiotensin ll receptor blocker for plaque vulnerability after percutaneous coronary intervention (PCI)

Phase 4
Conditions
Hypertension with coronary artery disease
Registration Number
JPRN-UMIN000001720
Lead Sponsor
The University of Tokushima, Cardiovascular Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Previous storoke<=6month 2) Ejection fraction<=40% 3) Patients with dialysis 4) Diabetic patients with HbA1c<=6.5 5) Patients who are treated with statin except pravastatin sodium

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in plaque composition and observation by Integrated Backscatter Intravascular Ultrasound (IB-IVUS)
Secondary Outcome Measures
NameTimeMethod
1) Change in surrogate marker in coronary vein blood hs-CRP,IL-6,TNF-alpha,IP-10,MMP-3, MMP-9,MCP-1,MIF,PTX-3,Heparin cofactor 2) Office blood pressure
© Copyright 2025. All Rights Reserved by MedPath